Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 23-Aug-24 4:10 PM View:  | Ra Capital Management, LLC 10% Owner | Fulcrum Therapeutics, Inc. (FULC) | 21-Aug-24 | Disposition (other) | 8,500,000 | -- | -- | (73%) 11.61M to 3.11M | |
| 08-Jul-24 8:00 AM View: | Sapir Alex See Remarks Director | Fulcrum Therapeutics, Inc. (FULC) | 03-Jul-24 | Option Exercise | 150,000 | $3.27 | $490,500.00 | 346% 43.36K to 193.36K | |
| 09-May-24 4:10 PM View: | Tourangeau Greg Principal Accounting Officer | Fulcrum Therapeutics, Inc. (FULC) | 07-May-24 | Sale | 236 | $7.76 | $1,831.36 | (2%) 11.81K to 11.57K | |
| 08-Mar-24 6:05 PM View: | Tourangeau Greg Vice President, Finance | Fulcrum Therapeutics, Inc. (FULC) | 08-Mar-24 | Sale | 4,884 | $11.72 | $57,218.50 | (29%) 16.69K to 11.81K | |
| 05-Mar-24 4:15 PM View: | Sapir Alex See Remarks Director | Fulcrum Therapeutics, Inc. (FULC) | 04-Mar-24 | Private Purchase | 43,360 | $11.35 | $492,028.00 | 100% 0 to 43.36K | |
| 11-May-23 4:12 PM View: | Tourangeau Greg Principal Accounting Officer | Fulcrum Therapeutics, Inc. (FULC) | 10-May-23 | Sale | 210 | $3.31 | $695.10 | (1%) 16.2K to 15.99K | |
| 24-Jan-23 4:30 PM View: | Ra Capital Management, LLC 10% Owner | Fulcrum Therapeutics, Inc. (FULC) | 20-Jan-23 | Private Purchase | 1,923,080 | $13.00 | $25,000,000.00 | 20% 9.69M to 11.61M | |
| 13-Jan-23 6:33 PM View: | Gould Robert J Interim President & CEO Director | Fulcrum Therapeutics, Inc. (FULC) | 13-Jan-23 | Market Sale (Planned) | 6,766 | $15.00 | $101,490.00 | (1%) 506.63K to 499.86K | (4%) |
| 06-Jan-23 4:39 PM View: | Ra Capital Management, LLC 10% Owner | Fulcrum Therapeutics, Inc. (FULC) | 04-Jan-23 | Private Purchase | 180,703 | $7.28 | $1,314,810.00 | < 1% 19.13M to 19.31M | |
| 29-Dec-22 5:00 PM View: | Ra Capital Management, LLC 10% Owner | Fulcrum Therapeutics, Inc. (FULC) | 27-Dec-22 | Private Purchase | 4,089 | $5.99 | $24,509.90 | < 1% 9.5M to 9.51M | |
| 21-Dec-22 4:30 PM View: | Ra Capital Management, LLC 10% Owner | Fulcrum Therapeutics, Inc. (FULC) | 19-Dec-22 | Private Purchase | 98,787 | $5.90 | $582,814.00 | 1% 9.4M to 9.5M | |
| 16-Dec-22 4:41 PM View: | Ra Capital Management, LLC 10% Owner | Fulcrum Therapeutics, Inc. (FULC) | 16-Dec-22 | Purchase | 1,341,420 | $5.42 | $7,269,830.00 | 6% 23.95M to 25.29M | |
| 16-Dec-22 4:41 PM View: | Ra Capital Management, LLC 10% Owner | Fulcrum Therapeutics, Inc. (FULC) | 15-Dec-22 | Purchase | 237,029 | $5.49 | $1,302,470.00 | < 1% 23.71M to 23.95M | |
| 16-Dec-22 4:41 PM View: | Ra Capital Management, LLC 10% Owner | Fulcrum Therapeutics, Inc. (FULC) | 14-Dec-22 | Private Purchase | 824,600 | $5.46 | $4,501,570.00 | 4% 22.89M to 23.71M | |
| 15-Dec-22 4:30 PM View: | Third Rock Ventures Iii, L.P. 10% Owner | Fulcrum Therapeutics, Inc. (FULC) | 13-Dec-22 | Disposition (other) | 2,000,000 | -- | -- | (31%) 6.46M to 4.46M | |
| 08-Jun-22 7:33 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 07-Jun-22 | Planned Option Sale | 71,435 | $8.09 | $577,895.00 | (12%) 578.07K to 506.63K | |
| 08-Jun-22 7:33 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 07-Jun-22 | Option Exercise | 71,435 | $7.84 | $560,050.00 | 14% 506.63K to 578.07K | |
| 06-Jun-22 7:00 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 06-Jun-22 | Option Exercise | 24,382 | $7.84 | $191,155.00 | 5% 506.63K to 531.01K | |
| 06-Jun-22 7:00 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 06-Jun-22 | Planned Option Sale | 24,382 | $8.10 | $197,592.00 | (5%) 531.01K to 506.63K | |
| 06-Jun-22 7:00 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 03-Jun-22 | Planned Option Sale | 25,551 | $7.95 | $203,056.00 | (5%) 532.18K to 506.63K | |
| 06-Jun-22 7:00 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 03-Jun-22 | Option Exercise | 25,551 | $7.84 | $200,320.00 | 5% 506.63K to 532.18K | |
| 06-Jun-22 7:00 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 02-Jun-22 | Planned Option Sale | 16,689 | $7.92 | $132,162.00 | (3%) 523.32K to 506.63K | |
| 06-Jun-22 7:00 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 02-Jun-22 | Option Exercise | 16,689 | $7.84 | $130,842.00 | 3% 506.63K to 523.32K | |
| 10-May-22 4:15 PM View: | Tourangeau Greg Controller | Fulcrum Therapeutics, Inc. (FULC) | 06-May-22 | Grant | 3,250 | -- | -- | 25% 12.95K to 16.2K | |
| 11-Apr-22 5:00 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 07-Apr-22 | Option Exercise | 5,631 | $7.84 | $44,147.00 | 1% 506.63K to 512.26K | |
| 11-Apr-22 5:00 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 07-Apr-22 | Planned Option Sale | 5,631 | $24.01 | $135,228.00 | (1%) 512.26K to 506.63K | |
| 05-Apr-22 7:00 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 05-Apr-22 | Planned Option Sale | 52,552 | $24.26 | $1,274,770.00 | (9%) 559.18K to 506.63K | |
| 05-Apr-22 7:00 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 05-Apr-22 | Option Exercise | 52,552 | $7.84 | $412,008.00 | 10% 506.63K to 559.18K | |
| 05-Apr-22 7:00 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 04-Apr-22 | Planned Option Sale | 7,235 | $24.02 | $173,749.00 | (1%) 513.87K to 506.63K | |
| 05-Apr-22 7:00 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 04-Apr-22 | Option Exercise | 7,235 | $7.84 | $56,722.40 | 1% 506.63K to 513.87K | |
| 05-Apr-22 7:00 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 01-Apr-22 | Option Exercise | 34,464 | $7.84 | $270,198.00 | 7% 506.63K to 541.09K | |
| 05-Apr-22 7:00 PM View: | Gould Robert J Director | Fulcrum Therapeutics, Inc. (FULC) | 01-Apr-22 | Planned Option Sale | 34,464 | $24.03 | $828,160.00 | (6%) 541.09K to 506.63K | |
| 07-Jan-22 10:00 PM View: | Oltmans Curtis Gale SVP, General Counsel | Fulcrum Therapeutics, Inc. (FULC) | 17-Dec-21 | Gift | 1,088 | -- | -- | (47%) 2.34K to 1.25K | |
| 12-Nov-21 5:31 PM View: | Levin Mark J Director 10% Owner | Fulcrum Therapeutics, Inc. (FULC) | 10-Nov-21 | Disposition (other) Duplicate | 1,000,000 | -- | -- | (20%) 5.05M to 4.05M | |
| 12-Nov-21 5:26 PM View: | Third Rock Ventures Iii, L.P. 10% Owner | Fulcrum Therapeutics, Inc. (FULC) | 10-Nov-21 | Disposition (other) | 1,000,000 | -- | -- | (13%) 7.47M to 6.47M | |
| 24-Sep-21 10:00 PM View: | Levin Mark J Director 10% Owner | Fulcrum Therapeutics, Inc. (FULC) | 22-Sep-21 | Disposition (other) Duplicate | 1,000,000 | -- | -- | (17%) 6.0M to 5.0M | |
| 24-Sep-21 10:00 PM View: | Third Rock Ventures Iii, L.P. 10% Owner | Fulcrum Therapeutics, Inc. (FULC) | 22-Sep-21 | Disposition (other) | 1,000,000 | -- | -- | (12%) 8.39M to 7.39M | |
| 12-Aug-21 4:20 PM View: | Stuart Bryan See Remarks Director | Fulcrum Therapeutics, Inc. (FULC) | 11-Aug-21 | Market Option Sale (Planned) | 28,000 | $23.75 | $665,000.00 | (100%) 28.0K to 0 | |
| 12-Aug-21 4:20 PM View: | Stuart Bryan See Remarks Director | Fulcrum Therapeutics, Inc. (FULC) | 11-Aug-21 | Option Exercise | 28,000 | $7.84 | $219,520.00 | 100% 0 to 28.0K | |
| 12-Aug-21 4:20 PM View: | Stuart Bryan See Remarks Director | Fulcrum Therapeutics, Inc. (FULC) | 10-Aug-21 | Option Exercise | 32,000 | $7.84 | $250,880.00 | 100% 0 to 32.0K | |
| 12-Aug-21 4:20 PM View: | Moxham Christopher Chief Scientific Officer | Fulcrum Therapeutics, Inc. (FULC) | 10-Aug-21 | Option Exercise | 51,785 | $7.84 | $405,994.00 | 167% 31.07K to 82.86K | |
| 12-Aug-21 4:20 PM View: | Moxham Christopher Chief Scientific Officer | Fulcrum Therapeutics, Inc. (FULC) | 10-Aug-21 | Market Option Sale (Planned) | 51,785 | $17.60 | $911,416.00 | (62%) 82.86K to 31.07K | |
| 12-Aug-21 4:20 PM View: | Stuart Bryan See Remarks Director | Fulcrum Therapeutics, Inc. (FULC) | 10-Aug-21 | Market Option Sale (Planned) | 32,000 | $17.50 | $560,000.00 | (100%) 32.0K to 0 | |
| 29-Jun-21 4:15 PM View: | Thomson Peter G. VP Finance & Accounting | Fulcrum Therapeutics, Inc. (FULC) | 28-Jun-21 | Market Purchase | 2,300 | $9.00 | $20,700.00 | 100% 0 to 2.3K | (< 1%) |
| 29-Jun-21 4:16 PM View: | Oltmans Curtis Gale SVP, General Counsel | Fulcrum Therapeutics, Inc. (FULC) | 28-Jun-21 | Market Purchase | 1,088 | $9.01 | $9,802.88 | 100% 0 to 1.09K | (1%) |
| 29-Jun-21 4:15 PM View: | Geraghty James A Director | Fulcrum Therapeutics, Inc. (FULC) | 28-Jun-21 | Market Purchase | 10,000 | $9.16 | $91,600.00 | 12% 80.71K to 90.71K | (3%) |
| 29-Jun-21 4:16 PM View: | Morabito Christopher Chief Medical Officer | Fulcrum Therapeutics, Inc. (FULC) | 28-Jun-21 | Market Purchase | 1,100 | $9.16 | $10,076.00 | 100% 0 to 1.1K | (3%) |
| 17-Mar-21 4:30 PM View: | Gould Robert J See Remarks Director | Fulcrum Therapeutics, Inc. (FULC) | 16-Mar-21 | Market Sale (Planned) | 789 | $12.43 | $9,805.61 | (< 1%) 507.42K to 506.63K | 2% |
| 17-Mar-21 4:30 PM View: | Gould Robert J See Remarks Director | Fulcrum Therapeutics, Inc. (FULC) | 15-Mar-21 | Market Sale (Planned) | 9,211 | $12.13 | $111,773.00 | (2%) 516.63K to 507.42K | (< 1%) |
| 24-Feb-21 4:30 PM View: | Thomson Peter G. VP Finance & Accounting | Fulcrum Therapeutics, Inc. (FULC) | 22-Feb-21 | Option Exercise | 5,000 | $7.84 | $39,200.00 | 33% 15.21K to 20.21K |
